Couldn’t attend this year’s Cell & Gene Therapies State of the Industry Briefing in-person or looking to have a copy of the slides to reference again? View the full webcast below and download the 2019 Industry Update PPT presentation.
To see all three of the video options click on the horizontal bars in the upper left corner.
Janet Lambert, CEO, Alliance for Regenerative Medicine
Joanne Beck, EVP, Global Pharmaceutical Development and Operations, Celgene Corporation
Maria Fardis, President and CEO, Iovance Biotherapeutics
Steven Kelly, President and CEO, CARISMA Therapeutics
Phil Vanek, General Manager, Cell Therapy Growth Strategies, GE Healthcare Life Sciences (chair)
Christopher Vann, Chief Operating Officer, Autolus Therapeutics
Dan Faga, Chief Business Officer, Spark Therapeutics
Matthew Kane, Co-Founder and CEO, Precision BioSciences
Matthew Patterson, Chairman and CEO, Audentes Therapeutics; Chairman, Alliance for Regenerative Medicine (chair)
Arthur Tzianabos, President and CEO, Homology Medicines
Jeffrey Walsh, Chief Financial and Strategy Officer, bluebird bio
Join us for the Alliance for Regenerative Medicine’s 9th Annual Cell & Gene Therapies State of the Industry Briefing, a top-level gathering for key stakeholders in the field. This event – which is free and open to the public – will highlight the commercialization of cell-based therapies for oncology, as well as an in-depth conversation between top CEOs and executives regarding future inflection points for gene therapies expected in 2019. With an anticipated audience of over 500, this session is the largest cell and gene therapy-focused event taking place during JP Morgan week.
55 Cyril Magnin St.
San Francisco, CA 94102
Over 500 of the cell and gene therapy field’s top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector’s recent advances and outlook for the industry in the coming year.
